Idenix Pharmaceuticals (IDIX)

[gofishmarko]

>> so there is clearly efficacy to the drug but it certainly doesn't look like it can bump riba from the regimen <<

It seems that NM283 adds about the same increment in antiviral activity to pegifn that riba does , in both naives and nonresponders. Off-treatment , however , it looks like the NM283/pegifn regimen is more like pegifn-only as to relapse rates , and thus significantly worse than pegifn/riba. If the 144 patients in the NM283 arms had instead been treated for 72 wks. with peg/riba , there would probably have been ~5-10 SVRs.

Because of higher relapse ( if this turns out to be true in the naive trial ) , a non-inferiority trial comparing NM283/peg to riba/peg is not a likely option , IMO. To do a P3 with riba , it would seem prudent to first do a decent-sized regimen-optimizing P2. Of course , by the time thay do that , VX-950
might be the new SOC.